泽马可、培菲康联合治疗便秘型肠易激综合征疗效分析

目的 探讨泽马可联合培菲康治疗便秘型肠易激综合征（C—irritable bowel syndrome,C-IBS）的临床疗效。方法 将肠易激综合征患者156例随机分为治疗组（A）和两个对照组（B、C），A组给予泽马可及培菲康，B组仅给予泽马可，C组仅给予培菲康，疗程4周．观察两组临床疗效。结果 A组缓解率为94．6％；B组为79．1％；C组为54．2％，三组疗效比较差异有统计学意义（P〈0．05）。结论 泽马可联合培菲康治疗便秘型肠易激综合征有明确的临床意义。

Analysis of the clinical effect on C-IBS treated with tegaserod and bifico combined

Objective To study the clinical effect on C-IBS treated with tegaserod and bifico combined. Methods 156 patients were randomly divided into one therapy group (group A) and two control group (group B, group C). Patients in the group A were given tegaserod and bifico therapy, while those in group B were given tegaserod therapy and group C were given bifico therapy. Results After 4 weeks' clinical treatment, the rates of remission were 94.6% in group A,7 9.1 % in group B and 54.2% in group C. There were significant statistical differences among three groups(P < 0.05). Conclusion The treatment with tegaserod and bifico combined on C-IBS had explicit clinical effect.